LYRA — Lyra Therapeutics Share News
0.000.00%
Last trade - 00:00- $0.34m
- -$15.56m
- $0.40m
Brief: Lyra Therapeutics Announces $15M Direct Offering and Private Placement Priced At-Market Under Nasdaq Rules
U.S. STOCKS ON THE MOVE-Natgas companies, UnitedHealth, Cactus
U.S. STOCKS ON THE MOVE-Lyra Therapeutics, Church & Dwight, Applied Digital
Lyra Therapeutics soars after nasal drug meets trial goals in late-stage study
Lyra Therapeutics soars after nasal drug meets trial goals in late-stage study
Brief: Lyra Therapeutics Reports Positive Results From The Enlighten 2 Phase 3 Trial Of Lyr-210
Lyra Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary
Lyra Therapeutics Inc expected to post a loss of 14 cents a share - Earnings Preview
Lyra Therapeutics Inc expected to post a loss of 14 cents a share - Earnings Preview
Lyra Therapeutics Inc reports results for the quarter ended September 30 - Earnings Summary
Lyra Therapeutics Inc expected to post a loss of 19 cents a share - Earnings Preview
Lyra Therapeutics Inc expected to post a loss of 23 cents a share - Earnings Preview
Brief: Lyra Therapeutics Says Topline Results From ENLIGHTEN 2 Expected In Q2 2025
Lyra Therapeutics Inc reports results for the quarter ended in June - Earnings Summary
Lyra Therapeutics Inc expected to post a loss of 33 cents a share - Earnings Preview
Lyra Therapeutics Inc expected to post a loss of 33 cents a share - Earnings Preview
Brief: Lyra Therapeutics Estimates It Will Incur Charges Of About $3.9 To $4.1 Mln In Connection With Workforce Reduction
Brief: Lyra Therapeutics Says Reduction In Force Included John E. Bishop, Company's Chief Technology Officer
Brief: Lyra Therapeutics Announces Cost-Cutting Measures To Preserve Capital